ArticleACS omega2026
Proteomics-Based Studies Identify the Metallothionein-2A as a Potential Target of Thioxo-Tetrahydropyrimidine Derivatives in Hepatocellular Carcinoma.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Novel tetrahydropyrimido-pyrimidine diones (THPP) (compounds 2d, 3d, 4d, and 19) and dihydropyrimidinones (DHPM) (compounds 2b, 4b, and 5b) have been synthesized and tested for their antioxidative capacities by assays based on their radical scavenging properties with 2,2'-azino-bis-(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) and 2,2-diphenyl-1-picrylhydrazyl (DPPH) assays, respectively. Reducing properties were determined using a Ferric Reducing Antioxidant Power assay (FRAP). Most of the THPPs exhibited more potent antioxidant effects compared to DHPMs. Anticancer activities were measured against brain (SW-1088, U87 MG), lung (A-549, H460), breast (MCF7, MDA-MB-231), liver (HepG2, HuH-7), and colon cancer (HCT 116, HT-29) cell lines. Among these, THPP derivatives (3d and 4d) have shown the most prominent anticancer activity in all tested cancer cell lines, with the highest potency observed in hepatocellular carcinoma cell lines HepG2 (IC
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.